InsiderSource
ALNY

ALNYLAM PHARMACEUTICALS, INC.

SEC CIK 1178670
$282.85 −19.6% · 90 days
90-day buys
$0
0 open-market
90-day sells
$2.42M
19 open-market
Net insider flow
−$2.42M
Net selling
Filings shown
143
Most recent

At a glance

Over the last 90 days, insiders at ALNY have sold a net $2.42M of stock (0 open-market buys vs 19 sells).

Largest recent trade: Greenstreet Yvonne sold $545.4K of ALNY, trimming their stake 2%.

Most active filer: Garg Pushkal, with 27 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for ALNY, newest first
View on SEC EDGAR ↗
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell McLaughlin Melissa · Chief Human Resources Officer · Open-market sale · filed Apr 7, 2026 ΔOwn −7.8%

Mclaughlin Melissa sold $299.8K of ALNY, trimming their stake 8%.

−$299.8K
909 sh @ $330
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell McLaughlin Melissa · Chief Human Resources Officer · Open-market sale · filed Apr 7, 2026 ΔOwn −7.7%

Mclaughlin Melissa sold $274K of ALNY, trimming their stake 8%.

−$274K
829 sh @ $330
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell McLaughlin Melissa · Chief Human Resources Officer · Open-market sale · filed Apr 7, 2026 ΔOwn −2.9%

Mclaughlin Melissa sold $97.2K of ALNY, trimming their stake 3%.

−$97.2K
293 sh @ $332
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell McLaughlin Melissa · Chief Human Resources Officer · Open-market sale · filed Apr 7, 2026 ΔOwn −2.1%

Mclaughlin Melissa sold $66.5K of ALNY, trimming their stake 2%.

−$66.5K
199 sh @ $334
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell McLaughlin Melissa · Chief Human Resources Officer · Open-market sale · filed Apr 7, 2026 ΔOwn −2.0%

Mclaughlin Melissa sold $83.9K of ALNY, trimming their stake 2%.

−$83.9K
265 sh @ $317
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell McLaughlin Melissa · Chief Human Resources Officer · Open-market sale · filed Apr 7, 2026 ΔOwn −2.7%

Mclaughlin Melissa sold $114K of ALNY, trimming their stake 3%.

−$114K
359 sh @ $317
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell McLaughlin Melissa · Chief Human Resources Officer · Open-market sale · filed Apr 7, 2026 ΔOwn −1.6%

Mclaughlin Melissa sold $66.6K of ALNY, trimming their stake 2%.

−$66.6K
209 sh @ $318
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell McLaughlin Melissa · Chief Human Resources Officer · Open-market sale · filed Apr 7, 2026 ΔOwn −0.7%

Mclaughlin Melissa sold $27.5K of ALNY, trimming their stake 1%.

−$27.5K
86 sh @ $320
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell McLaughlin Melissa · Chief Human Resources Officer · Open-market sale · filed Apr 7, 2026 ΔOwn −1.2%

Mclaughlin Melissa sold $47.1K of ALNY, trimming their stake 1%.

−$47.1K
147 sh @ $321
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell McLaughlin Melissa · Chief Human Resources Officer · Open-market sale · filed Apr 7, 2026 ΔOwn −2.0%

Mclaughlin Melissa sold $79.1K of ALNY, trimming their stake 2%.

−$79.1K
245 sh @ $323
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell McLaughlin Melissa · Chief Human Resources Officer · Open-market sale · filed Apr 7, 2026 ΔOwn −0.7%

Mclaughlin Melissa sold $26.2K of ALNY, trimming their stake 1%.

−$26.2K
81 sh @ $324
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Garg Pushkal · EVP Chief R&D · Open-market sale · filed Mar 6, 2026 ΔOwn −3.1%

Garg Pushkal sold $210.8K of ALNY, trimming their stake 3%.

−$210.8K
654 sh @ $322
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Garg Pushkal · EVP Chief R&D · Open-market sale · filed Mar 6, 2026 ΔOwn −3.6%

Garg Pushkal sold $239.4K of ALNY, trimming their stake 4%.

−$239.4K
740 sh @ $324
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Garg Pushkal · EVP Chief R&D · Open-market sale · filed Mar 6, 2026 ΔOwn −2.6%

Garg Pushkal sold $165.5K of ALNY, trimming their stake 3%.

−$165.5K
510 sh @ $325
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Garg Pushkal · EVP Chief R&D · Open-market sale · filed Mar 6, 2026 ΔOwn −2.6%

Garg Pushkal sold $163K of ALNY, trimming their stake 3%.

−$163K
500 sh @ $326
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Garg Pushkal · EVP Chief R&D · Open-market sale · filed Mar 6, 2026 ΔOwn −0.9%

Garg Pushkal sold $69K of ALNY, trimming their stake 1%.

−$69K
215 sh @ $321
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Garg Pushkal · EVP Chief R&D · Open-market sale · filed Mar 6, 2026 ΔOwn −1.3%

Garg Pushkal sold $93K of ALNY, trimming their stake 1%.

−$93K
289 sh @ $322
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Garg Pushkal · EVP Chief R&D · Open-market sale · filed Mar 6, 2026 ΔOwn −1.5%

Garg Pushkal sold $113.1K of ALNY, trimming their stake 2%.

−$113.1K
350 sh @ $323
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Garg Pushkal · EVP Chief R&D · Open-market sale · filed Mar 6, 2026 ΔOwn −3.4%

Garg Pushkal sold $248.4K of ALNY, trimming their stake 3%.

−$248.4K
767 sh @ $324
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Garg Pushkal · EVP Chief R&D · Open-market sale · filed Mar 6, 2026 ΔOwn −1.3%

Garg Pushkal sold $88.4K of ALNY, trimming their stake 1%.

−$88.4K
272 sh @ $325
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Garg Pushkal · EVP Chief R&D · Open-market sale · filed Mar 6, 2026 ΔOwn −1.0%

Garg Pushkal sold $67.7K of ALNY, trimming their stake 1%.

−$67.7K
208 sh @ $326
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Greenstreet Yvonne · Director, Chief Executive Officer · Open-market sale · filed Mar 6, 2026 ΔOwn −1.0%

Greenstreet Yvonne sold $315.1K of ALNY, trimming their stake 1%.

−$315.1K
973 sh @ $324
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Poulton Jeffrey V. · EVP, Chief Financial Officer · Open-market sale · filed Mar 6, 2026 ΔOwn −0.6%

Poulton Jeffrey V. sold $120.8K of ALNY, trimming their stake 1%.

−$120.8K
374 sh @ $323
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Poulton Jeffrey V. · EVP, Chief Financial Officer · Open-market sale · filed Mar 6, 2026 ΔOwn −1.3%

Poulton Jeffrey V. sold $264.9K of ALNY, trimming their stake 1%.

−$264.9K
818 sh @ $324
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Tanguler Tolga · EVP, Chief Commercial Officer · Open-market sale · filed Mar 6, 2026 ΔOwn −0.6%

Tanguler Tolga sold $69K of ALNY, trimming their stake 1%.

−$69K
215 sh @ $321
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Tanguler Tolga · EVP, Chief Commercial Officer · Open-market sale · filed Mar 6, 2026 ΔOwn −0.8%

Tanguler Tolga sold $93K of ALNY, trimming their stake 1%.

−$93K
289 sh @ $322
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Tanguler Tolga · EVP, Chief Commercial Officer · Open-market sale · filed Mar 6, 2026 ΔOwn −1.0%

Tanguler Tolga sold $113.1K of ALNY, trimming their stake 1%.

−$113.1K
350 sh @ $323
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Tanguler Tolga · EVP, Chief Commercial Officer · Open-market sale · filed Mar 6, 2026 ΔOwn −2.2%

Tanguler Tolga sold $248.4K of ALNY, trimming their stake 2%.

−$248.4K
767 sh @ $324
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Tanguler Tolga · EVP, Chief Commercial Officer · Open-market sale · filed Mar 6, 2026 ΔOwn −0.8%

Tanguler Tolga sold $88.4K of ALNY, trimming their stake 1%.

−$88.4K
272 sh @ $325
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Tanguler Tolga · EVP, Chief Commercial Officer · Open-market sale · filed Mar 6, 2026 ΔOwn −0.6%

Tanguler Tolga sold $67.7K of ALNY, trimming their stake 1%.

−$67.7K
208 sh @ $326
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Garg Pushkal · EVP Chief R&D · Open-market sale · filed Mar 4, 2026 ΔOwn −1.4%

Garg Pushkal sold $112.4K of ALNY, trimming their stake 1%.

−$112.4K
355 sh @ $317
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Garg Pushkal · EVP Chief R&D · Open-market sale · filed Mar 4, 2026 ΔOwn −1.3%

Garg Pushkal sold $101.1K of ALNY, trimming their stake 1%.

−$101.1K
317 sh @ $319
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Garg Pushkal · EVP Chief R&D · Open-market sale · filed Mar 4, 2026 ΔOwn −2.6%

Garg Pushkal sold $205.1K of ALNY, trimming their stake 3%.

−$205.1K
640 sh @ $320
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Garg Pushkal · EVP Chief R&D · Open-market sale · filed Mar 4, 2026 ΔOwn −1.9%

Garg Pushkal sold $148.9K of ALNY, trimming their stake 2%.

−$148.9K
463 sh @ $322
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Poulton Jeffrey V. · EVP, Chief Financial Officer · Open-market sale · filed Mar 4, 2026 ΔOwn −0.5%

Poulton Jeffrey V. sold $115.9K of ALNY, trimming their stake 1%.

−$115.9K
356 sh @ $326
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Poulton Jeffrey V. · EVP, Chief Financial Officer · Open-market sale · filed Mar 4, 2026 ΔOwn −0.8%

Poulton Jeffrey V. sold $176.8K of ALNY, trimming their stake 1%.

−$176.8K
541 sh @ $327
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Poulton Jeffrey V. · EVP, Chief Financial Officer · Open-market sale · filed Mar 4, 2026 ΔOwn −0.7%

Poulton Jeffrey V. sold $148.8K of ALNY, trimming their stake 1%.

−$148.8K
454 sh @ $328
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Garg Pushkal · EVP Chief R&D · Open-market sale · filed Mar 4, 2026 ΔOwn −1.0%

Garg Pushkal sold $90.2K of ALNY, trimming their stake 1%.

−$90.2K
277 sh @ $326
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Garg Pushkal · EVP Chief R&D · Open-market sale · filed Mar 4, 2026 ΔOwn −1.6%

Garg Pushkal sold $137.6K of ALNY, trimming their stake 2%.

−$137.6K
421 sh @ $327
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Garg Pushkal · EVP Chief R&D · Open-market sale · filed Mar 4, 2026 ΔOwn −1.4%

Garg Pushkal sold $115.7K of ALNY, trimming their stake 1%.

−$115.7K
353 sh @ $328
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Garg Pushkal · EVP Chief R&D · Open-market sale · filed Mar 4, 2026 ΔOwn −0.7%

Garg Pushkal sold $60K of ALNY, trimming their stake 1%.

−$60K
182 sh @ $330
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Tanguler Tolga · EVP, Chief Commercial Officer · Open-market sale · filed Mar 4, 2026 ΔOwn −0.7%

Tanguler Tolga sold $84K of ALNY, trimming their stake 1%.

−$84K
258 sh @ $326
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Tanguler Tolga · EVP, Chief Commercial Officer · Open-market sale · filed Mar 4, 2026 ΔOwn −1.0%

Tanguler Tolga sold $128.1K of ALNY, trimming their stake 1%.

−$128.1K
392 sh @ $327
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Tanguler Tolga · EVP, Chief Commercial Officer · Open-market sale · filed Mar 4, 2026 ΔOwn −0.9%

Tanguler Tolga sold $107.8K of ALNY, trimming their stake 1%.

−$107.8K
329 sh @ $328
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Greenstreet Yvonne · Director, Chief Executive Officer · Open-market sale · filed Mar 4, 2026 ΔOwn −1.0%

Greenstreet Yvonne sold $357.5K of ALNY, trimming their stake 1%.

−$357.5K
1,098 sh @ $326
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Greenstreet Yvonne · Director, Chief Executive Officer · Open-market sale · filed Mar 4, 2026 ΔOwn −1.6%

Greenstreet Yvonne sold $545.4K of ALNY, trimming their stake 2%.

−$545.4K
1,669 sh @ $327
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Greenstreet Yvonne · Director, Chief Executive Officer · Open-market sale · filed Mar 4, 2026 ΔOwn −1.4%

Greenstreet Yvonne sold $458.4K of ALNY, trimming their stake 1%.

−$458.4K
1,399 sh @ $328
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sell Greenstreet Yvonne · Director, Chief Executive Officer · Open-market sale · filed Mar 4, 2026 ΔOwn −0.7%

Greenstreet Yvonne sold $238.1K of ALNY, trimming their stake 1%.

−$238.1K
722 sh @ $330

About ALNY insider activity

This page tracks every recent Form 4 filed for ALNYLAM PHARMACEUTICALS, INC. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is ALNY insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for ALNYLAM PHARMACEUTICALS, INC. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.